Blocking HIV entry.
Targeting the fusogenic machinery of HIV with unnatural ligand libraries.
Buzko
O V
OV
Shokat
K M
KM
D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use; D000595:Amino Acid Sequence; D019380:Anti-HIV Agents / Q000138:chemical synthesis / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use; D020650:Combinatorial Chemistry Techniques; D015195:Drug Design; D015700:HIV Envelope Protein gp41 / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008024:Ligands; D008561:Membrane Fusion / Q000187:drug effects* / Q000276:immunology; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D019151:Peptide Library
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D008024:Ligands; D010446:Peptide Fragments; D019151:Peptide Library